Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 2-EU seeks large AstraZeneca fine for alleged contract breach

Wed, 26th May 2021 12:27

* EU lawyer says AstraZeneca did not even try to respect
contract

* "Not a contract for the delivery of shoes," AstraZeneca
lawyer

* EU wants a total of 120 mln doses to be delivered by end
of June
(Adds AstraZeneca lawyer, detail, paragraphs 5,8-9)

By Francesco Guarascio

BRUSSELS, May 26 (Reuters) - A lawyer for the European Union
accused AstraZeneca on Wednesday of failing to respect
its contract with the 27-nation bloc for the supply of COVID-19
vaccines and asked a Belgian court to impose a large fine on the
company.

The EU took the Anglo-Swedish firm to court in April after
the drugmaker said it would aim to deliver only 100 million
doses of its vaccine by the end of June, instead of the 300
million foreseen in the supply contract.

Brussels wants the company to deliver at least 120 million
vaccines by the end of June. AstraZeneca had delivered 50
million doses at the beginning of May, one-fourth of the 200
million vaccines foreseen in the contract by then.

"AstraZeneca did not even try to respect the contract," the
EU's lawyer, Rafael Jafferali, told a Brussels court in the
first hearing on the substance of the legal case.

He said the EU was seeking 10 euros ($12.2) for each day of
delay for each dose as compensation for AstraZeneca's
non-compliance with the EU contract. This penalty would apply
from July 1, 2021, if the judge accepted it.

The EU lawyer said the EU was seeking an additional penalty
of at least 10 million euros for each breach of the contract
that the judge may decide.

A verdict is expected next month.

NOT A CONTRACT FOR SHOES

"This is not a contract for the delivery of shoes or
T-shirts," AstraZeneca's lawyer Hakim Boularbah told the court
later on Wednesday, stressing the complexity of manufacturing a
new vaccine.

The company has repeatedly said the contract was not
binding as it only committed to make "best reasonable efforts"
in delivering doses. AstraZeneca's lawyer told the judge the
vaccine was sold at cost.

Jafferali said that principle had not been respected because
the drugmaker had not delivered to the bloc 50 million doses
produced in factories that are listed in the contract as
suppliers to the EU, of which 39 million doses manufactured in
Britain, 10 million produced in the United States and 1 million
in the Netherlands.

The lawyer said these doses were "diverted" to other
clients.

The company has said that doses produced in Britain were
reserved under a contract the British government signed with the
University of Oxford, which developed the vaccine.

Jafferali said AstraZeneca had pledged in the EU contract
not to have other engagements that would prevent it from abiding
by the terms of the deal.

The lawyer also said AstraZeneca had failed to communicate
to the EU in a timely manner the magnitude of its supply
problems because it repeatedly sent messages, including
publicly, that it was able to meet its targets, before finally
admitting there were large shortfalls in March.

The company had warned the EU in December of production
problems, but communicated only at the end of January, just
before the start of deliveries, a much larger cut than initially
expected for the first-quarter.

($1 = 0.8173 euros)
(Reporting by Francesco Guarascio @fraguarascio
editing by Kirsten Donovan and Jason Neely)

Related Shares

More News
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.